Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pragmatic management of progressive idiopathic pulmonary fibrosis
2019-004326-19Phase 3Active
- Sponsor
- Hospices Civils de Lyon
- Start
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of pirfenidone and nintedanib in idiopathic pulmonary fibrosis (IPF) (3 arms), sponsored by Hospices Civils de Lyon. Started Nov 2019; status: active.
02
Drugs
pirfenidonenintedanib
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on 2019-004326-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004326-19.